A deal with Regeneron announced in April could push the firm's revenue and income totals past $1 billion by year end.

The firm will use the funding to begin a pivotal study of its EGFR inhibitor, advance the Phase I study of its CLK inhibitor, and develop its preclinical pan-KRAS program.

The company is eyeing deals less than $2 billion, saying it has enough internal assets to replace losses from generic ...

The biotech plans to use the proceeds to develop its pipeline of in vivo CRISPR-based genetic medicines for cardiometabolic disease, including STX-1150.

Researchers at the Broad Institute, Jackson Laboratory, and Boston Children's Hospital will treat rare disease patients and ...

Biotech Immunome has given the first patient with a solid tumor its fibroblast activation protein (FAP)-targeted radioligand therapy within a clinical trial, the company announced Monday. The ...

If approved after priority review, the firm anticipates launching DYNE-251 in the US in the first quarter of next year.

Researchers are exploring delivering super-specific AAVs through the brain's natural waste disposal system, which can carry ...

A panel determined that Tafinlar and Adcetris will be offered to certain patients but passed on several other precision therapies.

The anti-amyloid drug is designed for a limited course, where patients can stop treatment once they reach a level of ...

The focus on treating people who have no cognitive impairment raises questions about how to implement testing for those at ...